PRDM14 Target
Breast Cancer
Key Facts
About ARIZ Precision Medicine
ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |